Sonali Bora
Psychiatry · Alpharetta, GANPI 1831375682
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 325 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,287, more than ten times the $207 reported in 2019.
Across 325 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$858
- Supernus Pharmaceuticals, Inc.$689
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$592
- Tris Pharma Inc$549
- AbbVie$533
- Corium, LLC$475
- plus $3K from 16 others
What the payments were for
- Food & beverage$6,21499%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 38 | $858 |
| Supernus Pharmaceuticals, Inc. | 30 | $689 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 41 | $592 |
| Tris Pharma Inc | 23 | $549 |
| AbbVie | 30 | $533 |
| Corium, LLC | 37 | $475 |
| Lundbeck LLC | 20 | $438 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $365 |
| Vanda Pharmaceuticals Inc. | 17 | $303 |
| Otsuka America Pharmaceutical, Inc. | 16 | $285 |
| Alkermes, Inc. | 3 | $236 |
| Teva Pharmaceuticals USA, Inc. | 5 | $226 |
| Ironshore Pharmaceuticals Inc. | 11 | $191 |
| Collegium Pharmaceutical, Inc. | 9 | $135 |
| Axsome Therapeutics, Inc. | 6 | $112 |
| Neos Therapeutics, LP | 6 | $102 |
| Vertical Pharmaceuticals, LLC | 3 | $48 |
| Neuronetics, Inc. | 3 | $43 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Tempus AI, Inc | 1 | $20 |
| Brainsway USA Inc | 1 | $17 |
| Avion Pharmaceuticals | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$480
- QELBREE$241
- Dyanavel XR$236
- Quillivant$236
- Quillichew ER$236
- SPRAVATO$142
- VRAYLAR$125
- ARISTADA INITIO$120
- Austedo XR$111
How this compares
$6,263 in reported general payments places this provider in the 85th percentile of 900 psychiatry providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Divalproex Sodium ErDivalproex Sodium | 11 | $329 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Alpharetta
- Angelo SambunarisAlpharetta$33K
- Richard PettyLoganville$2.9M
- Ann GrooverCalhoun$1.4M
- Todd AntinDecatur$1M
- Michael BanovMarietta$733K
- Ben HunterBrookhaven$499K
- Joel MorganValdosta$337K
- Munjal ShroffSmyrna$316K
- David PurselleAtlanta$307K
- Jose CangianoAthens$244K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.